Investigating vancomycin's effects on multiple sclerosis
Official title: Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis
Run by Icahn School of Medicine at Mount Sinai · NCT05539729 · Data updated 2026-11-12
This study is testing if the antibiotic vancomycin can change gut bacteria and help improve symptoms in people who have just been diagnosed with multiple sclerosis.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | January 31, 2023 |
| Main results expected | June 2028 |
| Study ends | December 2028 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT05539729 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 50 who have been newly diagnosed with multiple sclerosis and are treatment naive.
✕Probably not a fit
Patients with a history of other autoimmune diseases or recent antibiotic use may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore how vancomycin influences the gut-brain axis in patients with multiple sclerosis (MS). It will assess the impact of vancomycin on gut microbiota composition, peripheral immune function, and brain MRI lesions in newly diagnosed MS patients. By understanding these mechanisms, the research seeks to clarify the role of gut microbes in neuroinflammation associated with MS. Participants will be randomly assigned to receive either vancomycin or a placebo.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies for managing multiple sclerosis by targeting the gut microbiome.
How similar studies have gone: While the role of the gut microbiome in MS is being explored, this specific approach using vancomycin is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 18 - 50 * newly diagnosed MS (2017 McDonald criteria), CIS or RIS patients, who have experienced symptoms no earlier than the past year * treatment naive * able to understand the risks, benefits, and alternatives of participation and give meaningful consent Exclusion Criteria: * antibiotic use within the past 90 days; * pre- or probiotic use within past month or corticosteroids use within the past month; * use of tobacco products within the past 1 month; * history of treatment with immunosuppressants; * history of gastroenteritis within the past month or diagnosis with a chronic infectious disease, i.e. hepatitis B, C or HIV; * pregnancy or less than 6 months postpartum; * irritable bowel syndrome and other bowel dysfunction such as constipation; * history of bowel surgery; * inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, diabetes and any other auto-immune illness; * diagnosis with another neurological disease, behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study (such as severe major depression, schizophrenia and presence of psychotic symptoms); * eating disorders such as anorexia nervosa, bulimia, or binge eating syndrome; * travel outside of the country within the past month; * contraindication to vancomycin including estimated glomerular filtration rate of \<60ml/min, impaired hearing or known allergy. * Contraindication to MRI such as implanted metallic objects
Where it's running
-
Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Stephanie K Tankou, MD — Icahn School of Medicine
- Study coordinator: Susan E Filomena, BA
- Email: susan.filomena@mssm.edu
- Phone: 212-2413841
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.